DBTX Decibel Therapeutics

Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T.

A webcast of the fireside chat may be accessed by visiting the Investors section of the Decibel Therapeutics website at . An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the fireside chat.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy product candidate, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of creating a world of connection for people with hearing and balance disorders. For more information about Decibel Therapeutics, please visit or follow us on .

Investor Contact:

Julie Seidel

Stern Investor Relations, Inc.



212-362-1200

Media Contact:

Chris Railey

Ten Bridge Communications



617-834-0936



EN
17/05/2022

Underlying

DBTXDecibel Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Decibel Therapeutics

 PRESS RELEASE
Free
DBTX Decibel Therape...

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and...

Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update - Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy - - Announced on August 9 definitive agreement for Regeneron Pharmaceuticals to acquire Decibel - BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeu...

August 11, 2023 1 EN
 PRESS RELEASE
Free
DBTX Decibel Therape...

Decibel Therapeutics to Participate in the Upcoming Jefferies Healthca...

Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 12:45 p.m. E.T in New York, NY. A live webcast of the presentation may be accessed by visiting the Investors secti...

June 2, 2023 1 EN
 PRESS RELEASE
Free
DBTX Decibel Therape...

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at...

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Cli...

June 1, 2023 1 EN
 PRESS RELEASE
Free
DBTX Decibel Therape...

Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene...

Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Barclays 2023 Gene Editing and Gene Therapy Summit on Wednesday, May 24, 2023 at 10:30 a.m. E.T being held virtually. A live webcast of the presentation ...

May 17, 2023 1 EN
 PRESS RELEASE
Free
DBTX Decibel Therape...

Decibel Therapeutics Reports First Quarter 2023 Financial Results and ...

Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update - Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger - - Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in individuals with mutations in the GJB2 gene - BOSTON, May 15, 2023 (G...

May 15, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch